You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.
Cancel Ok

Olorinab

Olorinab

A drug candidate for the treatment of pain. Olorinab (APD371) is an investigational, oral, peripherally acting, highly selective, full agonist of the cannabinoid type 2 receptor (CB2). Olorinab is an internally discovered drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain associated with gastrointestinal disorders. This compound, through its selectivity for CB2 versus CB1, is under investigation for pain relief without psychoactive adverse effects.

CLINICAL TRIAL

  • TAKE A STAND AGAINST
    IBS PAIN
    CAPTIVATE is a Phase 2 clinical trial evaluating the efficacy and safety of oral olorinab in patients experiencing abdominal pain associated with irritable bowel syndrome (IBS).

    ClinicalTrials.gov: NCT04043455
Clinical Trials
IBS PAIN
Phase 2
IBD PAIN
Phase 1
Olorinab is an investigational drug and is not currently approved for use by any health authority.
Retained Rights: Worldwide.